{"id":"https://openalex.org/W2464047895","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7524","title":"A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).","display_name":"A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2464047895","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7524","mag":"2464047895"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.7524","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7524","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.7524","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032337115","display_name":"Nobuyuki Yamamoto","orcid":"https://orcid.org/0000-0002-7342-0853","observed_orcids":["https://orcid.org/0000-0002-7342-0853"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Yamamoto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102843956","display_name":"Nobuyuki Katakami","orcid":"https://orcid.org/0000-0002-1851-5788","observed_orcids":["https://orcid.org/0000-0002-1851-5788","https://orcid.org/0000-0001-8260-6441"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Katakami","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066357817","display_name":"Shinji Atagi","orcid":"https://orcid.org/0000-0003-1876-7069","observed_orcids":["https://orcid.org/0000-0003-1876-7069"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Atagi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"T. Hida","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Hida","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055202452","display_name":"Keiko Goto","orcid":"https://orcid.org/0000-0003-0620-3485","observed_orcids":["https://orcid.org/0000-0003-0620-3485"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Goto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112077489","display_name":"Takeshi Horai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Horai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065197178","display_name":"A. Inoue","orcid":"https://orcid.org/0000-0002-2954-2722","observed_orcids":["https://orcid.org/0000-0002-2954-2722"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Inoue","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113130155","display_name":"Y. Ichinose","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Ichinose","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037355181","display_name":"Keigo Kobayashi","orcid":"https://orcid.org/0000-0003-0609-9438","observed_orcids":["https://orcid.org/0000-0003-0609-9438"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Kobayashi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110529883","display_name":"K. Takeda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Takeda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066700160","display_name":"Katsuyuki Kiura","orcid":"https://orcid.org/0000-0002-9172-9379","observed_orcids":["https://orcid.org/0000-0002-9172-9379"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Kiura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101709104","display_name":"Hideo Saka","orcid":"https://orcid.org/0000-0001-7364-5115","observed_orcids":["https://orcid.org/0000-0001-7364-5115"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Saka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105411153","display_name":"Tomohide Tamura","orcid":"https://orcid.org/0000-0003-3601-8889","observed_orcids":["https://orcid.org/0000-0003-3601-8889"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Tamura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110475334","display_name":"Isamu Okamoto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I. Okamoto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042110139","display_name":"Naoyuki Nogami","orcid":"https://orcid.org/0000-0003-0278-4681","observed_orcids":["https://orcid.org/0000-0003-0278-4681"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Nogami","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000467384","display_name":"Ryotaro Morinaga","orcid":"https://orcid.org/0000-0002-0753-4318","observed_orcids":["https://orcid.org/0000-0002-0753-4318"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Morinaga","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004282323","display_name":"Kazuto Nishio","orcid":"https://orcid.org/0000-0002-8275-0846","observed_orcids":["https://orcid.org/0000-0002-8275-0846"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Nishio","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039221262","display_name":"Yoko Seki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Seki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069815454","display_name":"Robert M. Lorence","orcid":"https://orcid.org/0009-0001-6019-165X","observed_orcids":["https://orcid.org/0009-0001-6019-165X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. M. Lorence","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5038687249","display_name":"Maryam Shahidi","orcid":"https://orcid.org/0000-0001-9597-8308","observed_orcids":["https://orcid.org/0000-0001-9597-8308","https://orcid.org/0000-0003-4044-4696"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Shahidi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":25,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"7524","last_page":"7524"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.9039999842643738},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.7699999809265137},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.9449999928474426},{"id":"https://openalex.org/keywords/irreversible-egfr-inhibitors","display_name":"irreversible EGFR inhibitors","score":0.5580000281333923},{"id":"https://openalex.org/keywords/objective-response","display_name":"objective response","score":0.7289999723434448},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.8970000147819519},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9829999804496765},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.35600000619888306},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5899999737739563},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.3240000009536743}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9501800537109375},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.901351809501648},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.8195838928222656},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.800696611404419},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.7748650312423706},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6726455092430115},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5569037199020386},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5067916512489319},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44183316826820374},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44153591990470886},{"id":"https://openalex.org/C182707283","wikidata":"https://www.wikidata.org/wiki/Q7315622","display_name":"Resistance mutation","level":5,"score":0.42594215273857117},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.41977059841156006},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38143399357795715},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3674886226654053},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2923803925514221},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.18990564346313477},{"id":"https://openalex.org/C67705224","wikidata":"https://www.wikidata.org/wiki/Q11053","display_name":"RNA","level":3,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C156719811","wikidata":"https://www.wikidata.org/wiki/Q28774","display_name":"Reverse transcriptase","level":4,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.7524","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.7524","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.7524","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2332183914","https://openalex.org/W2132540363","https://openalex.org/W2032712631","https://openalex.org/W2969984880","https://openalex.org/W2046647306","https://openalex.org/W2599969362","https://openalex.org/W1998573252","https://openalex.org/W2999733661","https://openalex.org/W2015827831","https://openalex.org/W2947905396"],"abstract_inverted_index":{"7524":[0],"Background:":[1],"An":[2],"unmet":[3],"medical":[4],"need":[5],"exists":[6],"in":[7,23,51,56,68,159,243,267,305,319,337],"NSCLC":[8,73],"pts":[9,24,57,111,128,155,165,207,245,263],"after":[10,83],"failure":[11],"of":[12,33,86,91,127,140,148,154,164,169,206,256,286],"E":[13,63,92],"or":[14,64,93,123,179,184],"G":[15,94],"[reversible":[16],"EGFR":[17,27,157,176,317],"tyrosine":[18],"kinase":[19],"inhibitors":[20],"(TKIs)],":[21],"particularly":[22],"with":[25,70,134,143,209],"T790M":[26,265],"mutations,":[28],"the":[29,146,167,215,283],"most":[30],"common":[31],"mechanism":[32],"acquired":[34,60,170,247,312],"resistance.":[35],"Afatinib":[36,321],"(A),":[37],"an":[38],"irreversible":[39],"erbB":[40],"family":[41],"blocker,":[42],"has":[43,322],"preclinical":[44],"activity":[45],"against":[46],"T790M.":[47],"A":[48,98,149,210],"was":[49,104,150,222,236,241,288],"tested":[50],"this":[52,306],"phase":[53],"II":[54],"study":[55,307],"enriched":[58],"for":[59,187,311],"resistance":[61,171,248,313],"to":[62,81,172,182,192,314],"G.":[65],"Methods:":[66],"Pts":[67,304],"Japan":[69],"Stage":[71],"IIIB/IV":[72],"(ECOG":[74],"PS":[75],"0\u20131)":[76],"who":[77],"had":[78,118,129,211,264,274],"progressed":[79],"according":[80],"RECIST":[82],"1\u20132":[84],"lines":[85],"chemotherapy":[87],"and":[88,116,145,194,214,228,300,332],"\u226512":[89],"wks":[90,199,331],"received":[95,119],"50":[96],"mg":[97],"orally":[99],"qd.":[100],"The":[101],"primary":[102,161,269],"endpoint":[103],"objective":[105],"tumor":[106],"response.":[107],"Results:":[108],"Of":[109],"62":[110],"(F:48;":[112],"M:14),":[113],"11.3%,":[114],"79%":[115],"9.7%":[117],"prior":[120,132,141],"erlotinib,":[121],"gefitinib":[122],"both,":[124],"respectively.":[125],"65%":[126],"achieved":[130],"a":[131,212,275],"response":[133],"E/G.":[135,201],"Median":[136,234],"duration":[137],"between":[138],"end":[139],"treatment":[142],"E/G":[144,173,183,193],"start":[147],"3":[151],"wks.":[152],"73%":[153],"were":[156,226],"mutation-positive":[158],"their":[160,268],"tumors.":[162],"82%":[163],"met":[166],"definition":[168],"by":[174,231,259],"(1)":[175],"mutation":[177],"positive":[178],"(2)":[180],"CR/PR":[181],"(3)":[185],"SD":[186,277],"at":[188],"least":[189],"6":[190],"months":[191],"(4)":[195],"less":[196],"than":[197],"4":[198],"off":[200],"By":[202],"investigator":[203],"assessment,":[204],"13%":[205],"treated":[208],"PR":[213],"disease":[216],"control":[217],"rate":[218],"(DCR":[219],">8":[220,330],"wks)":[221],"72%;":[223],"these":[224,338],"values":[225],"8.2%":[227],"67%,":[229],"respectively,":[230],"independent":[232,260],"review.":[233],"PFS":[235,255],"4.6":[237],"months.":[238,290],"Similar":[239],"efficacy":[240,326],"seen":[242],"those":[244],"meeting":[246],"criteria":[249,310],"(5.9%":[250],"PR;":[251],"69%":[252,328],"DCR;":[253],"median":[254,335],"4.4":[257,333],"months,":[258],"review).":[261],"Two":[262],"mutations":[266],"tumors;":[270],"one,":[271],"harbouring":[272],"L858R+T790M,":[273],"long":[276],"(308":[278],"days).":[279],"At":[280],"data":[281],"cut-off,":[282],"25th":[284],"percentile":[285],"OS":[287],"10.6":[289],"Common":[291],"adverse":[292],"events":[293],"included":[294],"diarrhea,":[295],"rash/acne,":[296],"stomatitis,":[297],"nail":[298],"effects":[299],"decreased":[301],"appetite.":[302],"Conclusions:":[303],"largely":[308],"meet":[309],"first":[315],"generation":[316],"TKIs":[318],"NSCLC.":[320],"demonstrated":[323],"clinically":[324],"meaningful":[325],"(including":[327],"DCR":[329],"month":[334],"PFS)":[336],"pts.":[339]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2016-07-22T00:00:00"}